Multiple myeloma (MM) is a complex haematological malignancy that demands highly specialized laboratory testing to develop targeted therapies. In particular, multiple myeloma therapy development relies on precise biomarker identification, rigorous validation processes, and seamless global deployment of assays.
Our specialists support a wide range of MM studies from discovery to preclinical studies to phase III registration trials and beyond.
Over 95% of our projects include specialty testing, in particular, flow cytometry, cytogenetics, qPCR, ddPCR, NGS comprehensive myeloma panels, IHC simplex and multiplex protocols, and more.
Here’s an overview of the unique offerings at HBRI:
NGS, oncopanels,
broad panels, custom panels RNA seq, Single-gene CDNA-based panels ddPCR, qPCR
Whole exome / whole genome
HLA typing
TCR / BCR seq
NanoString®
SNP-array
DNA/RNA extraction
Streck Cell-Free DNA BCT®
PaxGene®, Qiamp kits
Coagulation Hematology Biochemistry
UrinalysisPregnancy test
COVID test
Serology
Thyroid function
HbA1c
All IMWG routine assays, such as sPER, uPER, sFLC
Multiplex cytokine profiling (37-plex)
50+ ligand binding assays
ELISA ELLA
MSD
ELISpot
EluroSpot assays
PK/ADA/Nab
Flow Cytometry
Cytek Aurora Immunophenotyping (including intra-cell markers)
Receptor occupancy
MRD detection (for MM by EuroFlow)
CAR T cell enumeration
CAR T cell phenotyping
Intracellular cytokine detection
PBMC isolation
BMMC isolation
Optical genome mapping, our next-generation cytogenetics
PK/ADA/Nab
Multiplex / simplex IHC
250+ biomarkers/protocols
Full histopath service Halo®, Visiopharm®
AI in image analysis
Board certified pathologists
Large biobank
Strong immuno-oncology simplex &
multiplex panels
Spatial analysis of the tumor
microenvironment
NanoString® GeoMx, FISH, ISH
We recommend starting engagement with our scientific team early, such as at the protocol design phase, for optimal results. We’re ready to discuss your needs.
Study 1: Started with one trial executed in our US laboratory on blood and BMA
Study 2: Then added another trial and another region, EU.
Flow Cytoretry panels were improved with this new trial
Study 2: Then added another region, AUS.
New flow cytometry instruments were installed and FCM panels were transferred to lab in Australia. Studies 3 & 4 quickly implemented the harmonized FCM panels in all regions
Multiple myeloma requires sophisticated biomarker analysis to guide treatment decisions and monitor patient response.
Here’s how our testing capabilities support your MM trials:
| Testing Focus | Methods & Markers | Clinical Application |
|---|---|---|
| Risk Stratification | Cytogenetics (del(17p), t(4;14), t(14;16), +1q21), flow cytometry immunophenotyping, NGS molecular profiling | Initial patient assessment and treatment planning |
| MRD Detection | Next-generation flow cytometry (10⁻⁵ to 10⁻⁶ sensitivity), Euroflow protocols, NGS-based detection | Primary endpoints, treatment response monitoring |
| Treatment Response | M-protein analysis, BCMA expression, CD38 levels, Immune microenvironment assessment | Therapy optimization and efficacy evaluation |
Minimal Residual Disease (MRD) Detection has become the gold standard for MM treatment assessment. Achieving MRD negativity is the strongest predictor of patient outcomes, making our ultra-sensitive detection methods essential for regulatory endpoints and clinical decision-making.
MM trials in the past 10 years
Of MM trials with specialty testing(s) and 45+ PBMC isolation network labs
Genes with our Cerba NGS extended panel for hematological malignancies
Histopathology analysis with markers such as CD138, kappa, lambda run in CLIA accredited laboratories
We recommend starting engagement with our scientific team early, such as at the protocol design phase, for optimal results. We’re ready to discuss your needs.
